A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA

Saved in:

Bibliographic Details
Published in:	Hematological oncology Vol. 35; no. S2; p. 260
Main Authors:	Gopal, A., Levy, R., Houot, R., Patel, S., Hatake, K., Popplewell, L., Chen, Y., Davis, C., Huang, B., Cesari, R., Thall, A., Woolfson, A., Bartlett, N.
Format:	Journal Article
Language:	English
Published:	Chichester Wiley Subscription Services, Inc 01-06-2017
Subjects:	CD137 antigen CD20 antigen Hodgkin's lymphoma Immunotherapy Lymphoma Monoclonal antibodies Non-Hodgkin's lymphoma Patients Rituximab Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	0278-0232 1099-1069
DOI:	10.1002/hon.2438_127